0001193125-15-418303.txt : 20151231 0001193125-15-418303.hdr.sgml : 20151231 20151231073230 ACCESSION NUMBER: 0001193125-15-418303 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20151228 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20151231 DATE AS OF CHANGE: 20151231 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HeartWare International, Inc. CENTRAL INDEX KEY: 0001389072 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980498958 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34256 FILM NUMBER: 151314973 BUSINESS ADDRESS: STREET 1: 500 OLD CONNECTICUT PATH CITY: FRAMINGHAM STATE: MA ZIP: 01701 BUSINESS PHONE: 508-739-0873 MAIL ADDRESS: STREET 1: 500 OLD CONNECTICUT PATH CITY: FRAMINGHAM STATE: MA ZIP: 01701 FORMER COMPANY: FORMER CONFORMED NAME: HeartWare LTD DATE OF NAME CHANGE: 20070206 8-K 1 d106402d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): December 28, 2015

 

 

HEARTWARE INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-34256   26-3636023

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

500 Old Connecticut Path

Framingham, MA 01701

(Address of principal executive offices)

Registrant’s telephone number, including area code: 508.739.0950

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events.

On December 28, 2015, HeartWare International, Inc. (“HeartWare”) received a notice from Engaged Capital, LLC (“Engaged Capital”) nominating three director candidates for election to HeartWare’s Board of Directors (the “Board”) at HeartWare’s 2016 Annual Meeting of Stockholders. In addition to the notice, Engaged Capital commented on HeartWare’s pending acquisition of Valtech Cardio, Ltd. (“Valtech”). In response, HeartWare issued a press release, a copy of which is attached hereto as Exhibit 99.1.

As previously announced, HeartWare intends to acquire Valtech as set forth in that certain Business Combination Agreement, dated as of September 1, 2015, by and among HeartWare, Valtech, HW Global, Inc., a Delaware corporation and a direct wholly owned subsidiary of HeartWare (“Holdco”), HW Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Holdco (“US Merger Sub”), Valor Merger Sub Ltd., a private company incorporated under the laws of Israel and a direct wholly owned subsidiary of Holdco (“ISR Merger Sub”) and Valor Shareholder Representative, LLC, a Delaware limited liability company, pursuant to which, subject to satisfaction or waiver of the conditions therein, HeartWare and Valtech will effect a strategic combination of their respective businesses under Holdco wherein (a) US Merger Sub shall merge with and into HeartWare, with HeartWare surviving the merger as a wholly owned subsidiary of Holdco (the “US Merger”), and (b) ISR Merger Sub shall merge with and into Valtech, with Valtech surviving the merger as a subsidiary of Holdco (the “ISR Merger,” together with the US Merger and the other transactions contemplated by the Business Combination Agreement, the “Transactions”).

Additional information concerning the proposed Transactions is included in the preliminary proxy statement/prospectus, which was originally filed by Holdco with the Securities and Exchange Commission on October 16, 2015 and amended on November 25, 2015.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

No.

   

Description

99.1    Press Release issued by HeartWare International, Inc. dated December 30, 2015.

Important Information

Additional Information about the Transactions and Where to Find It

In connection with the proposed Transactions, Holdco has filed a Registration Statement on Form S-4 that contains a preliminary proxy statement/prospectus, which is not yet final and may be further amended. Holdco intends to file a final prospectus and other relevant materials and HeartWare intends to file a definitive proxy statement and other relevant materials with the SEC in connection with the proposed Transactions. Investors and security holders of HeartWare and Valtech are urged to read these materials when they become available because they will contain important information about HeartWare, Valtech and the Transactions. The proxy statement/prospectus and other relevant materials (when they become available), and any other documents filed by Holdco or HeartWare with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Holdco or HeartWare by directing a written request to HeartWare’s investor relations department at HeartWare International, Inc., 500 Old Connecticut Path, Framingham, MA 01701, Attention: Investor Relations. Investors and security holders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the Transactions.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Participants in the Solicitation

HeartWare, Valtech and their respective directors, executive officers, certain members of management and certain employees may be deemed to be participants in the solicitation of proxies from the stockholders of HeartWare and Valtech in connection with the proposed Transactions. Information regarding the special interests of HeartWare’s directors and executive officers in the Transactions is included in the proxy statement/prospectus referred to above. Additional information regarding the directors and executive officers of HeartWare is also included in the HeartWare Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on March 2, 2015, as well as in HeartWare’s Definitive Proxy Statement for its 2015 Annual Meeting of Stockholders, which was filed with the SEC on April 30, 2015. These documents are available free of charge at the SEC’s website (www.sec.gov) and from Investor Relations at HeartWare at the address described above.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements, including, but not limited to, the ability of the parties to consummate the proposed Transactions; satisfaction of closing conditions to the consummation of the proposed Transactions; and such other risks and uncertainties pertaining to HeartWare’s business as detailed in its filings with the SEC on Forms 10-K and 10-Q, which are available on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof. HeartWare assumes no obligation to update any forward-looking statement contained in this document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    HeartWare International, Inc.
Date: December 31, 2015     By:  

/s/ Lawrence J. Knopf

    Name:   Lawrence J. Knopf
    Title:   Senior Vice President, General Counsel and Secretary

INDEX TO EXHIBITS

 

Exhibit

No.

   

Description

99.1    Press Release issued by HeartWare International, Inc. dated December 30, 2015.
 EX-99.1 2 d106402dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

HEARTWARE INTERNATIONAL CONFIRMS RECEIPT OF DIRECTOR NOMINATIONS NOTICE

— Company Remains Committed to Value-Enhancing Acquisition of Valtech Cardio, Ltd. —

Framingham, Mass., Dec. 30, 2015 – HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today confirmed that it has received a notice from Engaged Capital, LLC (“Engaged Capital”) nominating three director candidates for election to HeartWare’s Board of Directors (the “Board”) at the company’s 2016 Annual Meeting of Stockholders. HeartWare’s annual meeting, which historically has been held in June, has not yet been scheduled for 2016. HeartWare stockholders are not required to take any action at this time.

In addition to the notice, Engaged Capital commented on HeartWare’s pending acquisition of Valtech Cardio, Ltd. (“Valtech”), a privately held company that specializes in the development of innovative surgical and transcatheter valve repair and replacement devices for mitral and tricuspid regurgitation. HeartWare issued the following statement in response to Engaged Capital’s comments:

We disagree with Engaged Capital, which has become a HeartWare stockholder only recently and does not see the benefits of the Valtech transaction. We remain fully committed to this transaction and are encouraged by discussions with other stockholders as they have become more knowledgeable about strategic and financial merits of the business combination.

The addition of Valtech’s unique mitral and tricuspid repair and replacement platforms will position HeartWare for sustainable, long-term value on a larger scale than we believe could be achieved on a standalone basis. We believe the business combination will deepen and expand our presence in the global heart failure market, establishing us as the leader in two high-growth categories in the market, and positioning us to accelerate our long-term revenue growth and improve margins.

We are also encouraged by customer feedback from heart failure cardiologists, surgeons and interventional cardiologists around the world who recognize that this compelling combination will better enable them to treat patients. Other recent transactions in the market affirm our view that there is a significant and immediate unmet need for improved mitral repair technology, while replacement represents a major future opportunity in the mitral arena.

On September 1, 2015, HeartWare announced that it had entered into a definitive agreement to acquire Valtech. Valtech specializes in the development of innovative surgical and transcatheter valve repair and replacement devices for the treatment of the most prevalent heart valve diseases – mitral valve regurgitation (MR) and tricuspid valve regurgitation (TR). Approximately 4.2 million patients are affected by mitral valve disease in the U.S., which represents a multi-billion-dollar market opportunity. TR is estimated to affect 1.6 million patients in the U.S. and complements the mitral patient population, as a significant percentage of patients suffer from both MR and TR.

LOGO

 

HeartWare expects to announce in the coming weeks the date of its Special Meeting of HeartWare Stockholders (the “Special Meeting”) to vote on the pending acquisition of Valtech. The Special Meeting will be focused on the approval of the Valtech transaction only and is unrelated to the company’s Annual Meeting.

About HeartWare International

HeartWare International, Inc. develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare HVAD System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 47 countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit www.heartware.com.

Participants in the Solicitation

HeartWare, Valtech and their respective directors, executive officers, certain members of management and certain employees may be deemed to be participants in the solicitation of proxies in connection with the proposed acquisition of Valtech. A description of the interests in HeartWare of its directors and executive officers is set forth in HeartWare’s proxy statement for its 2015 Annual Meeting of Shareholders, which was filed with the Securities and Exchange Commission (the “SEC”) on April 30, 2015. This document is available free of charge at the SEC’s website at www.sec.gov or by going to HeartWare’s Investors page on its corporate website at www.heartware.com. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed Valtech transaction, and a description of their direct and indirect interests in the proposed transaction, which may differ from the interests of HeartWare stockholders or Valtech shareholders generally, are set forth in a preliminary proxy statement / prospectus originally filed with the SEC on October 16, 2015 and amended on November 25, 2015.

Additional Information and Where To Find It

In connection with the proposed Valtech transaction, HW Global, Inc. (“Holdco”), has filed a Registration Statement on Form S-4 that contains a preliminary proxy statement/prospectus, which is not yet final and may be further amended. Holdco intends to file a final prospectus and other relevant materials and HeartWare intends to file a definitive proxy statement and other relevant materials with the SEC in connection with the proposed Valtech Transaction. Investors and security holders of HeartWare and Valtech are urged to read these materials when they become available because they will contain important information about HeartWare, Valtech and the transaction. The proxy statement/prospectus and other relevant materials (when they become available), and any other documents filed by Holdco or HeartWare with the SEC, may be obtained free of charge at the SEC website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Holdco or HeartWare by directing a written request to HeartWare’s investor relations department at HeartWare International, Inc., 500 Old Connecticut Path, Framingham, MA 01701, Attention: Investor Relations. Investors and security holders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the Valtech transaction.

LOGO

 

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”).

Forward-Looking Statements

This announcement contains forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the: commercialization of the HeartWare HVAD System and introduction of the MVAD® System; timing, progress and outcomes of clinical trials; regulatory and quality compliance; research and development activities; consummation of our proposed acquisition of Valtech and our ability to take advantage of acquired and pipeline technology. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by federal securities laws and the rules and regulations of the SEC. HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation those described in Part I, Item 1A. “Risk Factors” in HeartWare’s Annual Report on Form 10-K filed with the SEC. HeartWare may update risk factors from time to time in Part II, Item 1A. “Risk Factors” in Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the SEC.

HEARTWARE, HVAD, MVAD, PAL, SYNERGY, CIRCULITE and HeartWare logos are trademarks of HeartWare, Inc. or its affiliates. VALTECH, CARDIOBAND, CARDINAL, CARDIOVALVE, V-CHORDAL and Valtech logos are trademarks of Valtech Cardio, Ltd.

Contacts:

Christopher Taylor

HeartWare International, Inc.

ctaylor@heartware.com

(508) 739-0864

Andrew Cole/Mark Harnett/Devin Broda

Sard Verbinnen & Co.

(212) 687-8080

# # #

GRAPHIC 3 g1064021.jpg GRAPHIC begin 644 g1064021.jpg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end GRAPHIC 4 g1064022.jpg GRAPHIC begin 644 g1064022.jpg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end